nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—UGT1A9—Mycophenolic acid—systemic scleroderma	0.0955	0.166	CbGbCtD
Sorafenib—UGT1A1—Mycophenolic acid—systemic scleroderma	0.0781	0.135	CbGbCtD
Sorafenib—UGT1A9—Mycophenolate mofetil—systemic scleroderma	0.0533	0.0925	CbGbCtD
Sorafenib—UGT1A1—Mycophenolate mofetil—systemic scleroderma	0.0436	0.0757	CbGbCtD
Sorafenib—ABCG2—Leflunomide—systemic scleroderma	0.0388	0.0674	CbGbCtD
Sorafenib—CYP2C8—Mometasone—systemic scleroderma	0.0321	0.0557	CbGbCtD
Sorafenib—ABCC2—Mycophenolate mofetil—systemic scleroderma	0.0265	0.046	CbGbCtD
Sorafenib—ABCG2—Mycophenolate mofetil—systemic scleroderma	0.024	0.0416	CbGbCtD
Sorafenib—ABCC4—Methotrexate—systemic scleroderma	0.0179	0.031	CbGbCtD
Sorafenib—CYP1A2—Pentoxifylline—systemic scleroderma	0.0168	0.0291	CbGbCtD
Sorafenib—CYP1A2—Leflunomide—systemic scleroderma	0.016	0.0278	CbGbCtD
Sorafenib—ABCB1—Lisinopril—systemic scleroderma	0.0147	0.0255	CbGbCtD
Sorafenib—CYP2C9—Leflunomide—systemic scleroderma	0.0144	0.025	CbGbCtD
Sorafenib—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.0133	0.0231	CbGbCtD
Sorafenib—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.0128	0.0222	CbGbCtD
Sorafenib—ABCB1—Captopril—systemic scleroderma	0.011	0.0191	CbGbCtD
Sorafenib—ABCC2—Methotrexate—systemic scleroderma	0.0106	0.0185	CbGbCtD
Sorafenib—CYP2D6—Captopril—systemic scleroderma	0.0104	0.018	CbGbCtD
Sorafenib—ABCG2—Methotrexate—systemic scleroderma	0.00962	0.0167	CbGbCtD
Sorafenib—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.00865	0.015	CbGbCtD
Sorafenib—CYP2C19—Prednisone—systemic scleroderma	0.00857	0.0149	CbGbCtD
Sorafenib—HTR2B—cardial valve—systemic scleroderma	0.00743	0.0664	CbGeAlD
Sorafenib—ABCB1—Prednisone—systemic scleroderma	0.00692	0.012	CbGbCtD
Sorafenib—KIT—myenteric nerve plexus—systemic scleroderma	0.00549	0.0491	CbGeAlD
Sorafenib—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.00518	0.00899	CbGbCtD
Sorafenib—CYP2C9—cardial valve—systemic scleroderma	0.00482	0.0431	CbGeAlD
Sorafenib—CYP3A4—Prednisone—systemic scleroderma	0.00414	0.00719	CbGbCtD
Sorafenib—CDK7—Mycophenolic acid—Mycophenolate mofetil—systemic scleroderma	0.00371	1	CbGdCrCtD
Sorafenib—ABCB1—Methotrexate—systemic scleroderma	0.00347	0.00602	CbGbCtD
Sorafenib—FLT1—umbilical vein—systemic scleroderma	0.00343	0.0307	CbGeAlD
Sorafenib—KDR—umbilical vein—systemic scleroderma	0.0029	0.0259	CbGeAlD
Sorafenib—TIE1—endothelium—systemic scleroderma	0.00253	0.0226	CbGeAlD
Sorafenib—MUSK—tendon—systemic scleroderma	0.00243	0.0217	CbGeAlD
Sorafenib—TIE1—blood vessel—systemic scleroderma	0.00233	0.0209	CbGeAlD
Sorafenib—FLT4—endothelium—systemic scleroderma	0.00209	0.0187	CbGeAlD
Sorafenib—FLT4—blood vessel—systemic scleroderma	0.00193	0.0172	CbGeAlD
Sorafenib—FLT1—artery—systemic scleroderma	0.00192	0.0172	CbGeAlD
Sorafenib—KDR—artery—systemic scleroderma	0.00163	0.0145	CbGeAlD
Sorafenib—FLT1—endothelium—systemic scleroderma	0.00163	0.0145	CbGeAlD
Sorafenib—CDK7—connective tissue—systemic scleroderma	0.00151	0.0135	CbGeAlD
Sorafenib—FLT1—blood vessel—systemic scleroderma	0.0015	0.0134	CbGeAlD
Sorafenib—KDR—endothelium—systemic scleroderma	0.00137	0.0123	CbGeAlD
Sorafenib—HIPK3—connective tissue—systemic scleroderma	0.00128	0.0114	CbGeAlD
Sorafenib—KDR—blood vessel—systemic scleroderma	0.00127	0.0113	CbGeAlD
Sorafenib—KIT—endothelium—systemic scleroderma	0.00122	0.0109	CbGeAlD
Sorafenib—KIT—blood vessel—systemic scleroderma	0.00112	0.01	CbGeAlD
Sorafenib—PDGFRB—blood vessel—systemic scleroderma	0.0011	0.00981	CbGeAlD
Sorafenib—TIE1—smooth muscle tissue—systemic scleroderma	0.00109	0.00978	CbGeAlD
Sorafenib—FLT3—connective tissue—systemic scleroderma	0.00109	0.00973	CbGeAlD
Sorafenib—TAOK2—tendon—systemic scleroderma	0.00103	0.00923	CbGeAlD
Sorafenib—AURKC—tendon—systemic scleroderma	0.00102	0.00915	CbGeAlD
Sorafenib—ZAK—digestive system—systemic scleroderma	0.000945	0.00845	CbGeAlD
Sorafenib—HIPK3—digestive system—systemic scleroderma	0.000925	0.00827	CbGeAlD
Sorafenib—CDK7—lung—systemic scleroderma	0.000913	0.00816	CbGeAlD
Sorafenib—TAOK2—lung—systemic scleroderma	0.000906	0.0081	CbGeAlD
Sorafenib—ZAK—tendon—systemic scleroderma	0.000899	0.00804	CbGeAlD
Sorafenib—MKNK2—connective tissue—systemic scleroderma	0.000895	0.008	CbGeAlD
Sorafenib—HIPK3—tendon—systemic scleroderma	0.00088	0.00787	CbGeAlD
Sorafenib—RET—connective tissue—systemic scleroderma	0.000873	0.0078	CbGeAlD
Sorafenib—MAP3K7—smooth muscle tissue—systemic scleroderma	0.000845	0.00755	CbGeAlD
Sorafenib—MKNK2—smooth muscle tissue—systemic scleroderma	0.000819	0.00732	CbGeAlD
Sorafenib—ZAK—lung—systemic scleroderma	0.000789	0.00705	CbGeAlD
Sorafenib—BRAF—tendon—systemic scleroderma	0.000788	0.00705	CbGeAlD
Sorafenib—HIPK3—lung—systemic scleroderma	0.000772	0.0069	CbGeAlD
Sorafenib—FLT1—connective tissue—systemic scleroderma	0.000769	0.00687	CbGeAlD
Sorafenib—RAF1—connective tissue—systemic scleroderma	0.000764	0.00683	CbGeAlD
Sorafenib—MAP3K19—lung—systemic scleroderma	0.000756	0.00676	CbGeAlD
Sorafenib—EPHX2—tendon—systemic scleroderma	0.000753	0.00674	CbGeAlD
Sorafenib—RALBP1—smooth muscle tissue—systemic scleroderma	0.000739	0.00661	CbGeAlD
Sorafenib—UGT1A9—digestive system—systemic scleroderma	0.000724	0.00647	CbGeAlD
Sorafenib—TIE1—lung—systemic scleroderma	0.000722	0.00645	CbGeAlD
Sorafenib—PDGFRA—connective tissue—systemic scleroderma	0.00072	0.00644	CbGeAlD
Sorafenib—FLT1—smooth muscle tissue—systemic scleroderma	0.000703	0.00629	CbGeAlD
Sorafenib—RAF1—smooth muscle tissue—systemic scleroderma	0.000699	0.00625	CbGeAlD
Sorafenib—BRAF—lung—systemic scleroderma	0.000692	0.00619	CbGeAlD
Sorafenib—RAF1—skin of body—systemic scleroderma	0.00069	0.00617	CbGeAlD
Sorafenib—EPHB6—skin of body—systemic scleroderma	0.000686	0.00613	CbGeAlD
Sorafenib—FGFR1—tendon—systemic scleroderma	0.00067	0.00599	CbGeAlD
Sorafenib—EPHX2—lung—systemic scleroderma	0.000661	0.00591	CbGeAlD
Sorafenib—PDGFRA—smooth muscle tissue—systemic scleroderma	0.000659	0.00589	CbGeAlD
Sorafenib—FLT3—lung—systemic scleroderma	0.000657	0.00587	CbGeAlD
Sorafenib—KDR—connective tissue—systemic scleroderma	0.00065	0.00581	CbGeAlD
Sorafenib—MKNK2—digestive system—systemic scleroderma	0.000646	0.00578	CbGeAlD
Sorafenib—MKNK1—digestive system—systemic scleroderma	0.000638	0.0057	CbGeAlD
Sorafenib—MAP3K7—tendon—systemic scleroderma	0.000635	0.00567	CbGeAlD
Sorafenib—CSF1R—connective tissue—systemic scleroderma	0.000634	0.00567	CbGeAlD
Sorafenib—RET—digestive system—systemic scleroderma	0.00063	0.00564	CbGeAlD
Sorafenib—MKNK2—tendon—systemic scleroderma	0.000615	0.0055	CbGeAlD
Sorafenib—RET—tendon—systemic scleroderma	0.0006	0.00536	CbGeAlD
Sorafenib—FLT4—lung—systemic scleroderma	0.000596	0.00533	CbGeAlD
Sorafenib—KDR—smooth muscle tissue—systemic scleroderma	0.000594	0.00531	CbGeAlD
Sorafenib—FGFR1—lung—systemic scleroderma	0.000588	0.00526	CbGeAlD
Sorafenib—RALBP1—digestive system—systemic scleroderma	0.000584	0.00522	CbGeAlD
Sorafenib—CSF1R—smooth muscle tissue—systemic scleroderma	0.00058	0.00519	CbGeAlD
Sorafenib—KIT—connective tissue—systemic scleroderma	0.000576	0.00515	CbGeAlD
Sorafenib—CSF1R—skin of body—systemic scleroderma	0.000573	0.00512	CbGeAlD
Sorafenib—PDGFRB—connective tissue—systemic scleroderma	0.000562	0.00503	CbGeAlD
Sorafenib—MAP3K7—lung—systemic scleroderma	0.000557	0.00498	CbGeAlD
Sorafenib—RALBP1—tendon—systemic scleroderma	0.000555	0.00497	CbGeAlD
Sorafenib—FLT1—digestive system—systemic scleroderma	0.000555	0.00496	CbGeAlD
Sorafenib—RAF1—digestive system—systemic scleroderma	0.000552	0.00493	CbGeAlD
Sorafenib—MKNK2—lung—systemic scleroderma	0.00054	0.00483	CbGeAlD
Sorafenib—MKNK1—lung—systemic scleroderma	0.000533	0.00476	CbGeAlD
Sorafenib—FLT1—tendon—systemic scleroderma	0.000528	0.00472	CbGeAlD
Sorafenib—KIT—smooth muscle tissue—systemic scleroderma	0.000527	0.00471	CbGeAlD
Sorafenib—STK10—digestive system—systemic scleroderma	0.000526	0.0047	CbGeAlD
Sorafenib—RAF1—tendon—systemic scleroderma	0.000525	0.0047	CbGeAlD
Sorafenib—EPHB6—tendon—systemic scleroderma	0.000522	0.00467	CbGeAlD
Sorafenib—PDGFRA—digestive system—systemic scleroderma	0.00052	0.00465	CbGeAlD
Sorafenib—KIT—skin of body—systemic scleroderma	0.00052	0.00465	CbGeAlD
Sorafenib—PDGFRB—smooth muscle tissue—systemic scleroderma	0.000514	0.0046	CbGeAlD
Sorafenib—PDGFRB—skin of body—systemic scleroderma	0.000508	0.00454	CbGeAlD
Sorafenib—STK10—tendon—systemic scleroderma	0.0005	0.00447	CbGeAlD
Sorafenib—UGT1A1—digestive system—systemic scleroderma	0.000496	0.00444	CbGeAlD
Sorafenib—PDGFRA—tendon—systemic scleroderma	0.000495	0.00443	CbGeAlD
Sorafenib—RALBP1—lung—systemic scleroderma	0.000487	0.00436	CbGeAlD
Sorafenib—KDR—digestive system—systemic scleroderma	0.000469	0.0042	CbGeAlD
Sorafenib—FLT1—lung—systemic scleroderma	0.000464	0.00414	CbGeAlD
Sorafenib—RAF1—lung—systemic scleroderma	0.000461	0.00412	CbGeAlD
Sorafenib—EPHB6—lung—systemic scleroderma	0.000458	0.0041	CbGeAlD
Sorafenib—CSF1R—digestive system—systemic scleroderma	0.000458	0.00409	CbGeAlD
Sorafenib—KDR—tendon—systemic scleroderma	0.000447	0.00399	CbGeAlD
Sorafenib—MAP2K5—tendon—systemic scleroderma	0.000447	0.00399	CbGeAlD
Sorafenib—STK10—lung—systemic scleroderma	0.000439	0.00392	CbGeAlD
Sorafenib—CSF1R—tendon—systemic scleroderma	0.000436	0.0039	CbGeAlD
Sorafenib—PDGFRA—lung—systemic scleroderma	0.000434	0.00388	CbGeAlD
Sorafenib—KIT—digestive system—systemic scleroderma	0.000416	0.00372	CbGeAlD
Sorafenib—HTR2B—smooth muscle tissue—systemic scleroderma	0.000407	0.00364	CbGeAlD
Sorafenib—PDGFRB—digestive system—systemic scleroderma	0.000406	0.00363	CbGeAlD
Sorafenib—HTR2B—skin of body—systemic scleroderma	0.000402	0.0036	CbGeAlD
Sorafenib—MAP2K5—lung—systemic scleroderma	0.000392	0.0035	CbGeAlD
Sorafenib—KDR—lung—systemic scleroderma	0.000392	0.0035	CbGeAlD
Sorafenib—PDGFRB—tendon—systemic scleroderma	0.000387	0.00346	CbGeAlD
Sorafenib—CSF1R—lung—systemic scleroderma	0.000382	0.00342	CbGeAlD
Sorafenib—KIT—lung—systemic scleroderma	0.000347	0.00311	CbGeAlD
Sorafenib—PDGFRB—lung—systemic scleroderma	0.000339	0.00303	CbGeAlD
Sorafenib—ABCC4—digestive system—systemic scleroderma	0.000323	0.00289	CbGeAlD
Sorafenib—HTR2B—digestive system—systemic scleroderma	0.000322	0.00288	CbGeAlD
Sorafenib—ABCC2—digestive system—systemic scleroderma	0.000313	0.0028	CbGeAlD
Sorafenib—ABCC4—tendon—systemic scleroderma	0.000308	0.00275	CbGeAlD
Sorafenib—HTR2B—tendon—systemic scleroderma	0.000306	0.00274	CbGeAlD
Sorafenib—ABCB1—blood vessel—systemic scleroderma	0.000304	0.00272	CbGeAlD
Sorafenib—ABCC2—tendon—systemic scleroderma	0.000298	0.00266	CbGeAlD
Sorafenib—ABCC4—lung—systemic scleroderma	0.00027	0.00241	CbGeAlD
Sorafenib—CYP2C19—digestive system—systemic scleroderma	0.000269	0.0024	CbGeAlD
Sorafenib—HTR2B—lung—systemic scleroderma	0.000269	0.0024	CbGeAlD
Sorafenib—CYP2B6—skin of body—systemic scleroderma	0.000263	0.00235	CbGeAlD
Sorafenib—CYP1A2—digestive system—systemic scleroderma	0.00022	0.00196	CbGeAlD
Sorafenib—CYP3A5—digestive system—systemic scleroderma	0.000212	0.00189	CbGeAlD
Sorafenib—CYP2B6—digestive system—systemic scleroderma	0.000211	0.00188	CbGeAlD
Sorafenib—CYP2C9—digestive system—systemic scleroderma	0.000209	0.00186	CbGeAlD
Sorafenib—ABCG2—lung—systemic scleroderma	0.000191	0.0017	CbGeAlD
Sorafenib—CYP1A2—lung—systemic scleroderma	0.000184	0.00164	CbGeAlD
Sorafenib—CYP3A5—lung—systemic scleroderma	0.000177	0.00158	CbGeAlD
Sorafenib—CYP2B6—lung—systemic scleroderma	0.000176	0.00157	CbGeAlD
Sorafenib—CYP3A4—digestive system—systemic scleroderma	0.000159	0.00142	CbGeAlD
Sorafenib—Dyspnoea—Leflunomide—systemic scleroderma	0.000157	0.000827	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000157	0.000826	CcSEcCtD
Sorafenib—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.000157	0.000823	CcSEcCtD
Sorafenib—CYP2D6—digestive system—systemic scleroderma	0.000157	0.0014	CbGeAlD
Sorafenib—Dyspepsia—Leflunomide—systemic scleroderma	0.000155	0.000817	CcSEcCtD
Sorafenib—Pancreatitis—Prednisone—systemic scleroderma	0.000155	0.000816	CcSEcCtD
Sorafenib—Vomiting—Mometasone—systemic scleroderma	0.000155	0.000815	CcSEcCtD
Sorafenib—Dry mouth—Lisinopril—systemic scleroderma	0.000155	0.000813	CcSEcCtD
Sorafenib—Rash—Mometasone—systemic scleroderma	0.000154	0.000808	CcSEcCtD
Sorafenib—Asthenia—Captopril—systemic scleroderma	0.000154	0.000808	CcSEcCtD
Sorafenib—Dermatitis—Mometasone—systemic scleroderma	0.000154	0.000807	CcSEcCtD
Sorafenib—Decreased appetite—Leflunomide—systemic scleroderma	0.000153	0.000807	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000153	0.000806	CcSEcCtD
Sorafenib—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000153	0.000803	CcSEcCtD
Sorafenib—Headache—Mometasone—systemic scleroderma	0.000153	0.000803	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000152	0.000801	CcSEcCtD
Sorafenib—Fatigue—Leflunomide—systemic scleroderma	0.000152	0.0008	CcSEcCtD
Sorafenib—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000152	0.000797	CcSEcCtD
Sorafenib—Pruritus—Captopril—systemic scleroderma	0.000152	0.000797	CcSEcCtD
Sorafenib—Pain—Leflunomide—systemic scleroderma	0.000151	0.000793	CcSEcCtD
Sorafenib—Constipation—Leflunomide—systemic scleroderma	0.000151	0.000793	CcSEcCtD
Sorafenib—Infection—Lisinopril—systemic scleroderma	0.000151	0.000792	CcSEcCtD
Sorafenib—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000151	0.000791	CcSEcCtD
Sorafenib—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.00015	0.000789	CcSEcCtD
Sorafenib—Shock—Lisinopril—systemic scleroderma	0.000149	0.000784	CcSEcCtD
Sorafenib—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000149	0.000782	CcSEcCtD
Sorafenib—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000149	0.000781	CcSEcCtD
Sorafenib—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000148	0.000779	CcSEcCtD
Sorafenib—Neutropenia—Prednisone—systemic scleroderma	0.000148	0.000779	CcSEcCtD
Sorafenib—Abdominal pain—Azathioprine—systemic scleroderma	0.000148	0.000777	CcSEcCtD
Sorafenib—Body temperature increased—Azathioprine—systemic scleroderma	0.000148	0.000777	CcSEcCtD
Sorafenib—Skin disorder—Lisinopril—systemic scleroderma	0.000147	0.000774	CcSEcCtD
Sorafenib—Diarrhoea—Captopril—systemic scleroderma	0.000147	0.00077	CcSEcCtD
Sorafenib—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000146	0.000769	CcSEcCtD
Sorafenib—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000146	0.000768	CcSEcCtD
Sorafenib—Erectile dysfunction—Prednisone—systemic scleroderma	0.000146	0.000767	CcSEcCtD
Sorafenib—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000146	0.000766	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000145	0.000764	CcSEcCtD
Sorafenib—Fatigue—Mycophenolic acid—systemic scleroderma	0.000145	0.000763	CcSEcCtD
Sorafenib—Mood swings—Methotrexate—systemic scleroderma	0.000145	0.000763	CcSEcCtD
Sorafenib—Nausea—Mometasone—systemic scleroderma	0.000145	0.000761	CcSEcCtD
Sorafenib—Anorexia—Lisinopril—systemic scleroderma	0.000145	0.00076	CcSEcCtD
Sorafenib—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000144	0.000759	CcSEcCtD
Sorafenib—Pain—Mycophenolic acid—systemic scleroderma	0.000144	0.000757	CcSEcCtD
Sorafenib—Constipation—Mycophenolic acid—systemic scleroderma	0.000144	0.000757	CcSEcCtD
Sorafenib—Weight decreased—Prednisone—systemic scleroderma	0.000143	0.000753	CcSEcCtD
Sorafenib—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000143	0.000752	CcSEcCtD
Sorafenib—Cough—Mycophenolate mofetil—systemic scleroderma	0.000142	0.000747	CcSEcCtD
Sorafenib—Dizziness—Captopril—systemic scleroderma	0.000142	0.000744	CcSEcCtD
Sorafenib—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000141	0.000739	CcSEcCtD
Sorafenib—Urticaria—Leflunomide—systemic scleroderma	0.00014	0.000737	CcSEcCtD
Sorafenib—Body temperature increased—Leflunomide—systemic scleroderma	0.00014	0.000733	CcSEcCtD
Sorafenib—Abdominal pain—Leflunomide—systemic scleroderma	0.00014	0.000733	CcSEcCtD
Sorafenib—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000139	0.000732	CcSEcCtD
Sorafenib—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000139	0.000729	CcSEcCtD
Sorafenib—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000139	0.000729	CcSEcCtD
Sorafenib—Myocardial infarction—Prednisone—systemic scleroderma	0.000138	0.000728	CcSEcCtD
Sorafenib—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000138	0.000728	CcSEcCtD
Sorafenib—Breast disorder—Methotrexate—systemic scleroderma	0.000138	0.000728	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000138	0.000726	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000138	0.000725	CcSEcCtD
Sorafenib—Hypersensitivity—Azathioprine—systemic scleroderma	0.000138	0.000724	CcSEcCtD
Sorafenib—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000138	0.000724	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000138	0.000724	CcSEcCtD
Sorafenib—Vomiting—Captopril—systemic scleroderma	0.000136	0.000716	CcSEcCtD
Sorafenib—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000136	0.000713	CcSEcCtD
Sorafenib—Dyspnoea—Lisinopril—systemic scleroderma	0.000135	0.000711	CcSEcCtD
Sorafenib—Rash—Captopril—systemic scleroderma	0.000135	0.00071	CcSEcCtD
Sorafenib—Dermatitis—Captopril—systemic scleroderma	0.000135	0.000709	CcSEcCtD
Sorafenib—Headache—Captopril—systemic scleroderma	0.000134	0.000705	CcSEcCtD
Sorafenib—Dyspepsia—Lisinopril—systemic scleroderma	0.000134	0.000702	CcSEcCtD
Sorafenib—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000133	0.0007	CcSEcCtD
Sorafenib—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000133	0.0007	CcSEcCtD
Sorafenib—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000133	0.000699	CcSEcCtD
Sorafenib—Infection—Mycophenolate mofetil—systemic scleroderma	0.000132	0.000694	CcSEcCtD
Sorafenib—Decreased appetite—Lisinopril—systemic scleroderma	0.000132	0.000693	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000131	0.000688	CcSEcCtD
Sorafenib—Fatigue—Lisinopril—systemic scleroderma	0.000131	0.000687	CcSEcCtD
Sorafenib—Shock—Mycophenolate mofetil—systemic scleroderma	0.000131	0.000687	CcSEcCtD
Sorafenib—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00013	0.000685	CcSEcCtD
Sorafenib—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.00013	0.000684	CcSEcCtD
Sorafenib—Hypersensitivity—Leflunomide—systemic scleroderma	0.00013	0.000684	CcSEcCtD
Sorafenib—Pancreatitis—Methotrexate—systemic scleroderma	0.00013	0.000682	CcSEcCtD
Sorafenib—Constipation—Lisinopril—systemic scleroderma	0.00013	0.000682	CcSEcCtD
Sorafenib—Pain—Lisinopril—systemic scleroderma	0.00013	0.000682	CcSEcCtD
Sorafenib—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000129	0.000679	CcSEcCtD
Sorafenib—Diarrhoea—Azathioprine—systemic scleroderma	0.000128	0.000672	CcSEcCtD
Sorafenib—Haemoglobin—Prednisone—systemic scleroderma	0.000127	0.00067	CcSEcCtD
Sorafenib—Nausea—Captopril—systemic scleroderma	0.000127	0.000669	CcSEcCtD
Sorafenib—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000127	0.000667	CcSEcCtD
Sorafenib—Haemorrhage—Prednisone—systemic scleroderma	0.000127	0.000666	CcSEcCtD
Sorafenib—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000127	0.000666	CcSEcCtD
Sorafenib—Asthenia—Leflunomide—systemic scleroderma	0.000127	0.000666	CcSEcCtD
Sorafenib—Pruritus—Leflunomide—systemic scleroderma	0.000125	0.000656	CcSEcCtD
Sorafenib—Connective tissue disorder—Prednisone—systemic scleroderma	0.000125	0.000655	CcSEcCtD
Sorafenib—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000124	0.000652	CcSEcCtD
Sorafenib—Neutropenia—Methotrexate—systemic scleroderma	0.000124	0.000651	CcSEcCtD
Sorafenib—Dizziness—Azathioprine—systemic scleroderma	0.000124	0.00065	CcSEcCtD
Sorafenib—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000122	0.000641	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000121	0.000636	CcSEcCtD
Sorafenib—Asthenia—Mycophenolic acid—systemic scleroderma	0.000121	0.000635	CcSEcCtD
Sorafenib—Diarrhoea—Leflunomide—systemic scleroderma	0.000121	0.000635	CcSEcCtD
Sorafenib—Urticaria—Lisinopril—systemic scleroderma	0.000121	0.000633	CcSEcCtD
Sorafenib—Abdominal pain—Lisinopril—systemic scleroderma	0.00012	0.00063	CcSEcCtD
Sorafenib—Body temperature increased—Lisinopril—systemic scleroderma	0.00012	0.00063	CcSEcCtD
Sorafenib—Pruritus—Mycophenolic acid—systemic scleroderma	0.000119	0.000626	CcSEcCtD
Sorafenib—Vomiting—Azathioprine—systemic scleroderma	0.000119	0.000625	CcSEcCtD
Sorafenib—Pneumonia—Methotrexate—systemic scleroderma	0.000119	0.000624	CcSEcCtD
Sorafenib—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000118	0.000623	CcSEcCtD
Sorafenib—Infestation NOS—Methotrexate—systemic scleroderma	0.000118	0.00062	CcSEcCtD
Sorafenib—Infestation—Methotrexate—systemic scleroderma	0.000118	0.00062	CcSEcCtD
Sorafenib—Rash—Azathioprine—systemic scleroderma	0.000118	0.00062	CcSEcCtD
Sorafenib—Dermatitis—Azathioprine—systemic scleroderma	0.000118	0.000619	CcSEcCtD
Sorafenib—Flushing—Prednisone—systemic scleroderma	0.000118	0.000619	CcSEcCtD
Sorafenib—Headache—Azathioprine—systemic scleroderma	0.000117	0.000616	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000117	0.000615	CcSEcCtD
Sorafenib—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000117	0.000615	CcSEcCtD
Sorafenib—Dizziness—Leflunomide—systemic scleroderma	0.000117	0.000614	CcSEcCtD
Sorafenib—Renal failure—Methotrexate—systemic scleroderma	0.000116	0.00061	CcSEcCtD
Sorafenib—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000116	0.000607	CcSEcCtD
Sorafenib—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000115	0.000606	CcSEcCtD
Sorafenib—Stomatitis—Methotrexate—systemic scleroderma	0.000115	0.000605	CcSEcCtD
Sorafenib—Angiopathy—Prednisone—systemic scleroderma	0.000115	0.000605	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000115	0.000603	CcSEcCtD
Sorafenib—Immune system disorder—Prednisone—systemic scleroderma	0.000115	0.000602	CcSEcCtD
Sorafenib—Pain—Mycophenolate mofetil—systemic scleroderma	0.000114	0.000597	CcSEcCtD
Sorafenib—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000114	0.000597	CcSEcCtD
Sorafenib—Arrhythmia—Prednisone—systemic scleroderma	0.000113	0.000595	CcSEcCtD
Sorafenib—ABCB1—digestive system—systemic scleroderma	0.000113	0.00101	CbGeAlD
Sorafenib—Vomiting—Leflunomide—systemic scleroderma	0.000112	0.00059	CcSEcCtD
Sorafenib—Alopecia—Prednisone—systemic scleroderma	0.000112	0.000589	CcSEcCtD
Sorafenib—Hypersensitivity—Lisinopril—systemic scleroderma	0.000112	0.000587	CcSEcCtD
Sorafenib—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000112	0.000587	CcSEcCtD
Sorafenib—Dizziness—Mycophenolic acid—systemic scleroderma	0.000111	0.000585	CcSEcCtD
Sorafenib—Epistaxis—Methotrexate—systemic scleroderma	0.000111	0.000585	CcSEcCtD
Sorafenib—Rash—Leflunomide—systemic scleroderma	0.000111	0.000585	CcSEcCtD
Sorafenib—Dermatitis—Leflunomide—systemic scleroderma	0.000111	0.000584	CcSEcCtD
Sorafenib—Mental disorder—Prednisone—systemic scleroderma	0.000111	0.000584	CcSEcCtD
Sorafenib—Nausea—Azathioprine—systemic scleroderma	0.000111	0.000584	CcSEcCtD
Sorafenib—Headache—Leflunomide—systemic scleroderma	0.000111	0.000581	CcSEcCtD
Sorafenib—Erythema—Prednisone—systemic scleroderma	0.00011	0.00058	CcSEcCtD
Sorafenib—Malnutrition—Prednisone—systemic scleroderma	0.00011	0.00058	CcSEcCtD
Sorafenib—Asthenia—Lisinopril—systemic scleroderma	0.000109	0.000572	CcSEcCtD
Sorafenib—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000109	0.000571	CcSEcCtD
Sorafenib—Pruritus—Lisinopril—systemic scleroderma	0.000107	0.000564	CcSEcCtD
Sorafenib—Vomiting—Mycophenolic acid—systemic scleroderma	0.000107	0.000563	CcSEcCtD
Sorafenib—Haemoglobin—Methotrexate—systemic scleroderma	0.000107	0.00056	CcSEcCtD
Sorafenib—Rash—Mycophenolic acid—systemic scleroderma	0.000106	0.000558	CcSEcCtD
Sorafenib—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000106	0.000558	CcSEcCtD
Sorafenib—Haemorrhage—Methotrexate—systemic scleroderma	0.000106	0.000557	CcSEcCtD
Sorafenib—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000555	CcSEcCtD
Sorafenib—Headache—Mycophenolic acid—systemic scleroderma	0.000105	0.000555	CcSEcCtD
Sorafenib—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000105	0.000552	CcSEcCtD
Sorafenib—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000105	0.000552	CcSEcCtD
Sorafenib—Nausea—Leflunomide—systemic scleroderma	0.000105	0.000551	CcSEcCtD
Sorafenib—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000105	0.00055	CcSEcCtD
Sorafenib—Urethral disorder—Methotrexate—systemic scleroderma	0.000104	0.000546	CcSEcCtD
Sorafenib—Diarrhoea—Lisinopril—systemic scleroderma	0.000104	0.000546	CcSEcCtD
Sorafenib—Anaemia—Prednisone—systemic scleroderma	0.000102	0.000536	CcSEcCtD
Sorafenib—Angioedema—Prednisone—systemic scleroderma	0.000101	0.00053	CcSEcCtD
Sorafenib—Dizziness—Lisinopril—systemic scleroderma	0.0001	0.000527	CcSEcCtD
Sorafenib—Erythema multiforme—Methotrexate—systemic scleroderma	0.0001	0.000527	CcSEcCtD
Sorafenib—Nausea—Mycophenolic acid—systemic scleroderma	0.0001	0.000526	CcSEcCtD
Sorafenib—Syncope—Prednisone—systemic scleroderma	9.9e-05	0.00052	CcSEcCtD
Sorafenib—Tinnitus—Methotrexate—systemic scleroderma	9.88e-05	0.000519	CcSEcCtD
Sorafenib—Cardiac disorder—Methotrexate—systemic scleroderma	9.83e-05	0.000517	CcSEcCtD
Sorafenib—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	9.79e-05	0.000515	CcSEcCtD
Sorafenib—Loss of consciousness—Prednisone—systemic scleroderma	9.7e-05	0.00051	CcSEcCtD
Sorafenib—Vomiting—Lisinopril—systemic scleroderma	9.64e-05	0.000507	CcSEcCtD
Sorafenib—Angiopathy—Methotrexate—systemic scleroderma	9.61e-05	0.000505	CcSEcCtD
Sorafenib—Immune system disorder—Methotrexate—systemic scleroderma	9.57e-05	0.000503	CcSEcCtD
Sorafenib—Rash—Lisinopril—systemic scleroderma	9.56e-05	0.000503	CcSEcCtD
Sorafenib—Dermatitis—Lisinopril—systemic scleroderma	9.56e-05	0.000502	CcSEcCtD
Sorafenib—Mediastinal disorder—Methotrexate—systemic scleroderma	9.55e-05	0.000502	CcSEcCtD
Sorafenib—Asthenia—Mycophenolate mofetil—systemic scleroderma	9.54e-05	0.000501	CcSEcCtD
Sorafenib—Hypertension—Prednisone—systemic scleroderma	9.53e-05	0.000501	CcSEcCtD
Sorafenib—Headache—Lisinopril—systemic scleroderma	9.5e-05	0.000499	CcSEcCtD
Sorafenib—Pruritus—Mycophenolate mofetil—systemic scleroderma	9.4e-05	0.000494	CcSEcCtD
Sorafenib—ABCB1—lung—systemic scleroderma	9.4e-05	0.000841	CbGeAlD
Sorafenib—Myalgia—Prednisone—systemic scleroderma	9.4e-05	0.000494	CcSEcCtD
Sorafenib—Arthralgia—Prednisone—systemic scleroderma	9.4e-05	0.000494	CcSEcCtD
Sorafenib—Alopecia—Methotrexate—systemic scleroderma	9.36e-05	0.000492	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	9.33e-05	0.000491	CcSEcCtD
Sorafenib—Mental disorder—Methotrexate—systemic scleroderma	9.28e-05	0.000488	CcSEcCtD
Sorafenib—Erythema—Methotrexate—systemic scleroderma	9.22e-05	0.000485	CcSEcCtD
Sorafenib—Malnutrition—Methotrexate—systemic scleroderma	9.22e-05	0.000485	CcSEcCtD
Sorafenib—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	9.09e-05	0.000478	CcSEcCtD
Sorafenib—Dysgeusia—Methotrexate—systemic scleroderma	9.03e-05	0.000475	CcSEcCtD
Sorafenib—Nausea—Lisinopril—systemic scleroderma	9.01e-05	0.000474	CcSEcCtD
Sorafenib—Anaphylactic shock—Prednisone—systemic scleroderma	9.01e-05	0.000474	CcSEcCtD
Sorafenib—Infection—Prednisone—systemic scleroderma	8.95e-05	0.00047	CcSEcCtD
Sorafenib—Shock—Prednisone—systemic scleroderma	8.86e-05	0.000466	CcSEcCtD
Sorafenib—Nervous system disorder—Prednisone—systemic scleroderma	8.83e-05	0.000464	CcSEcCtD
Sorafenib—Dizziness—Mycophenolate mofetil—systemic scleroderma	8.79e-05	0.000462	CcSEcCtD
Sorafenib—Skin disorder—Prednisone—systemic scleroderma	8.75e-05	0.00046	CcSEcCtD
Sorafenib—Anorexia—Prednisone—systemic scleroderma	8.59e-05	0.000451	CcSEcCtD
Sorafenib—Anaemia—Methotrexate—systemic scleroderma	8.53e-05	0.000448	CcSEcCtD
Sorafenib—Vomiting—Mycophenolate mofetil—systemic scleroderma	8.45e-05	0.000444	CcSEcCtD
Sorafenib—Rash—Mycophenolate mofetil—systemic scleroderma	8.38e-05	0.00044	CcSEcCtD
Sorafenib—Dermatitis—Mycophenolate mofetil—systemic scleroderma	8.37e-05	0.00044	CcSEcCtD
Sorafenib—Headache—Mycophenolate mofetil—systemic scleroderma	8.33e-05	0.000438	CcSEcCtD
Sorafenib—Leukopenia—Methotrexate—systemic scleroderma	8.26e-05	0.000434	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Prednisone—systemic scleroderma	8.21e-05	0.000431	CcSEcCtD
Sorafenib—Cough—Methotrexate—systemic scleroderma	8.05e-05	0.000423	CcSEcCtD
Sorafenib—Dyspepsia—Prednisone—systemic scleroderma	7.93e-05	0.000417	CcSEcCtD
Sorafenib—Nausea—Mycophenolate mofetil—systemic scleroderma	7.89e-05	0.000415	CcSEcCtD
Sorafenib—Myalgia—Methotrexate—systemic scleroderma	7.85e-05	0.000413	CcSEcCtD
Sorafenib—Arthralgia—Methotrexate—systemic scleroderma	7.85e-05	0.000413	CcSEcCtD
Sorafenib—Decreased appetite—Prednisone—systemic scleroderma	7.83e-05	0.000412	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	7.8e-05	0.00041	CcSEcCtD
Sorafenib—Fatigue—Prednisone—systemic scleroderma	7.77e-05	0.000408	CcSEcCtD
Sorafenib—Constipation—Prednisone—systemic scleroderma	7.7e-05	0.000405	CcSEcCtD
Sorafenib—Anaphylactic shock—Methotrexate—systemic scleroderma	7.53e-05	0.000396	CcSEcCtD
Sorafenib—Infection—Methotrexate—systemic scleroderma	7.48e-05	0.000393	CcSEcCtD
Sorafenib—Nervous system disorder—Methotrexate—systemic scleroderma	7.38e-05	0.000388	CcSEcCtD
Sorafenib—Thrombocytopenia—Methotrexate—systemic scleroderma	7.37e-05	0.000387	CcSEcCtD
Sorafenib—Gastrointestinal pain—Prednisone—systemic scleroderma	7.37e-05	0.000387	CcSEcCtD
Sorafenib—Skin disorder—Methotrexate—systemic scleroderma	7.31e-05	0.000384	CcSEcCtD
Sorafenib—Anorexia—Methotrexate—systemic scleroderma	7.18e-05	0.000377	CcSEcCtD
Sorafenib—Urticaria—Prednisone—systemic scleroderma	7.16e-05	0.000376	CcSEcCtD
Sorafenib—Abdominal pain—Prednisone—systemic scleroderma	7.12e-05	0.000374	CcSEcCtD
Sorafenib—Body temperature increased—Prednisone—systemic scleroderma	7.12e-05	0.000374	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	6.86e-05	0.000361	CcSEcCtD
Sorafenib—Dyspnoea—Methotrexate—systemic scleroderma	6.71e-05	0.000353	CcSEcCtD
Sorafenib—Hypersensitivity—Prednisone—systemic scleroderma	6.64e-05	0.000349	CcSEcCtD
Sorafenib—Dyspepsia—Methotrexate—systemic scleroderma	6.63e-05	0.000348	CcSEcCtD
Sorafenib—Decreased appetite—Methotrexate—systemic scleroderma	6.54e-05	0.000344	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Methotrexate—systemic scleroderma	6.5e-05	0.000342	CcSEcCtD
Sorafenib—Fatigue—Methotrexate—systemic scleroderma	6.49e-05	0.000341	CcSEcCtD
Sorafenib—Asthenia—Prednisone—systemic scleroderma	6.46e-05	0.00034	CcSEcCtD
Sorafenib—Pain—Methotrexate—systemic scleroderma	6.44e-05	0.000338	CcSEcCtD
Sorafenib—Pruritus—Prednisone—systemic scleroderma	6.37e-05	0.000335	CcSEcCtD
Sorafenib—Diarrhoea—Prednisone—systemic scleroderma	6.16e-05	0.000324	CcSEcCtD
Sorafenib—Gastrointestinal pain—Methotrexate—systemic scleroderma	6.16e-05	0.000324	CcSEcCtD
Sorafenib—Urticaria—Methotrexate—systemic scleroderma	5.98e-05	0.000314	CcSEcCtD
Sorafenib—Dizziness—Prednisone—systemic scleroderma	5.96e-05	0.000313	CcSEcCtD
Sorafenib—Body temperature increased—Methotrexate—systemic scleroderma	5.95e-05	0.000313	CcSEcCtD
Sorafenib—Abdominal pain—Methotrexate—systemic scleroderma	5.95e-05	0.000313	CcSEcCtD
Sorafenib—Vomiting—Prednisone—systemic scleroderma	5.73e-05	0.000301	CcSEcCtD
Sorafenib—Rash—Prednisone—systemic scleroderma	5.68e-05	0.000299	CcSEcCtD
Sorafenib—Dermatitis—Prednisone—systemic scleroderma	5.67e-05	0.000298	CcSEcCtD
Sorafenib—Headache—Prednisone—systemic scleroderma	5.64e-05	0.000297	CcSEcCtD
Sorafenib—Hypersensitivity—Methotrexate—systemic scleroderma	5.55e-05	0.000292	CcSEcCtD
Sorafenib—Asthenia—Methotrexate—systemic scleroderma	5.4e-05	0.000284	CcSEcCtD
Sorafenib—Nausea—Prednisone—systemic scleroderma	5.35e-05	0.000281	CcSEcCtD
Sorafenib—Pruritus—Methotrexate—systemic scleroderma	5.33e-05	0.00028	CcSEcCtD
Sorafenib—Diarrhoea—Methotrexate—systemic scleroderma	5.15e-05	0.000271	CcSEcCtD
Sorafenib—Dizziness—Methotrexate—systemic scleroderma	4.98e-05	0.000262	CcSEcCtD
Sorafenib—Vomiting—Methotrexate—systemic scleroderma	4.79e-05	0.000252	CcSEcCtD
Sorafenib—Rash—Methotrexate—systemic scleroderma	4.75e-05	0.00025	CcSEcCtD
Sorafenib—Dermatitis—Methotrexate—systemic scleroderma	4.74e-05	0.000249	CcSEcCtD
Sorafenib—Headache—Methotrexate—systemic scleroderma	4.72e-05	0.000248	CcSEcCtD
Sorafenib—Nausea—Methotrexate—systemic scleroderma	4.47e-05	0.000235	CcSEcCtD
Sorafenib—MAPK11—Signaling Pathways—HSPG2—systemic scleroderma	2.58e-05	0.000219	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—BLK—systemic scleroderma	2.58e-05	0.000219	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—CD247—systemic scleroderma	2.57e-05	0.000219	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.57e-05	0.000219	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—HSPG2—systemic scleroderma	2.56e-05	0.000217	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—HLA-DQB1—systemic scleroderma	2.55e-05	0.000217	CbGpPWpGaD
Sorafenib—RAF1—Disease—HSPG2—systemic scleroderma	2.52e-05	0.000215	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CSK—systemic scleroderma	2.49e-05	0.000212	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IRF8—systemic scleroderma	2.48e-05	0.000211	CbGpPWpGaD
Sorafenib—RAF1—Immune System—ITGAM—systemic scleroderma	2.48e-05	0.000211	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CD247—systemic scleroderma	2.48e-05	0.000211	CbGpPWpGaD
Sorafenib—RAF1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	2.48e-05	0.000211	CbGpPWpGaD
Sorafenib—KIT—Immune System—CTLA4—systemic scleroderma	2.48e-05	0.000211	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—CTLA4—systemic scleroderma	2.48e-05	0.000211	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CSK—systemic scleroderma	2.47e-05	0.00021	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—RHOB—systemic scleroderma	2.47e-05	0.00021	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—RHOB—systemic scleroderma	2.47e-05	0.00021	CbGpPWpGaD
Sorafenib—FGFR1—Axon guidance—MMP9—systemic scleroderma	2.46e-05	0.000209	CbGpPWpGaD
Sorafenib—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	2.45e-05	0.000208	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—EDN1—systemic scleroderma	2.44e-05	0.000208	CbGpPWpGaD
Sorafenib—RAF1—Disease—CSK—systemic scleroderma	2.44e-05	0.000207	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—SMAD7—systemic scleroderma	2.42e-05	0.000206	CbGpPWpGaD
Sorafenib—EPHX2—Metabolism—NOS3—systemic scleroderma	2.42e-05	0.000206	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—CD40LG—systemic scleroderma	2.41e-05	0.000205	CbGpPWpGaD
Sorafenib—KDR—Developmental Biology—MMP9—systemic scleroderma	2.39e-05	0.000203	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—MMP1—systemic scleroderma	2.37e-05	0.000202	CbGpPWpGaD
Sorafenib—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	2.37e-05	0.000202	CbGpPWpGaD
Sorafenib—MKNK1—Disease—NOS3—systemic scleroderma	2.36e-05	0.000201	CbGpPWpGaD
Sorafenib—RAF1—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	2.35e-05	0.0002	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CTLA4—systemic scleroderma	2.35e-05	0.0002	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CTLA4—systemic scleroderma	2.34e-05	0.000199	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—RHOB—systemic scleroderma	2.34e-05	0.000199	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—MMP2—systemic scleroderma	2.34e-05	0.000199	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—RHOB—systemic scleroderma	2.33e-05	0.000199	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—HSPG2—systemic scleroderma	2.33e-05	0.000198	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—HSPG2—systemic scleroderma	2.33e-05	0.000198	CbGpPWpGaD
Sorafenib—RAF1—Immune System—TNFAIP3—systemic scleroderma	2.32e-05	0.000198	CbGpPWpGaD
Sorafenib—HTR2B—GPCR ligand binding—CCL2—systemic scleroderma	2.31e-05	0.000196	CbGpPWpGaD
Sorafenib—RAF1—Immune System—BLK—systemic scleroderma	2.3e-05	0.000195	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.29e-05	0.000195	CbGpPWpGaD
Sorafenib—RAF1—Disease—CD247—systemic scleroderma	2.29e-05	0.000195	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—CCL2—systemic scleroderma	2.27e-05	0.000193	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—HLA-DQB1—systemic scleroderma	2.26e-05	0.000192	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CSK—systemic scleroderma	2.25e-05	0.000191	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CSK—systemic scleroderma	2.25e-05	0.000191	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—CCL2—systemic scleroderma	2.24e-05	0.00019	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HSPG2—systemic scleroderma	2.21e-05	0.000188	CbGpPWpGaD
Sorafenib—RAF1—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	2.21e-05	0.000188	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HSPG2—systemic scleroderma	2.2e-05	0.000187	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—HSPG2—systemic scleroderma	2.17e-05	0.000185	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—HSPG2—systemic scleroderma	2.17e-05	0.000185	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL1A—systemic scleroderma	2.15e-05	0.000183	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—CD40LG—systemic scleroderma	2.14e-05	0.000182	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CSK—systemic scleroderma	2.13e-05	0.000181	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CSK—systemic scleroderma	2.13e-05	0.000181	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CTLA4—systemic scleroderma	2.11e-05	0.00018	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—RHOB—systemic scleroderma	2.1e-05	0.000179	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SMAD7—systemic scleroderma	2.09e-05	0.000178	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.09e-05	0.000178	CbGpPWpGaD
Sorafenib—MAPK11—Developmental Biology—MMP9—systemic scleroderma	2.05e-05	0.000175	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—NOS3—systemic scleroderma	2.05e-05	0.000174	CbGpPWpGaD
Sorafenib—KIT—Immune System—HLA-DQB1—systemic scleroderma	2.04e-05	0.000173	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—HLA-DQB1—systemic scleroderma	2.04e-05	0.000173	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—NOS3—systemic scleroderma	2.03e-05	0.000172	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—RHOB—systemic scleroderma	2.01e-05	0.000171	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—NOS3—systemic scleroderma	1.99e-05	0.00017	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HSPG2—systemic scleroderma	1.98e-05	0.000169	CbGpPWpGaD
Sorafenib—RAF1—Axon guidance—MMP9—systemic scleroderma	1.97e-05	0.000168	CbGpPWpGaD
Sorafenib—KDR—Developmental Biology—TGFB1—systemic scleroderma	1.97e-05	0.000167	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.95e-05	0.000166	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL1A—systemic scleroderma	1.94e-05	0.000165	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL1A—systemic scleroderma	1.94e-05	0.000165	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—HLA-DQB1—systemic scleroderma	1.93e-05	0.000165	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—HLA-DQB1—systemic scleroderma	1.93e-05	0.000164	CbGpPWpGaD
Sorafenib—KIT—Immune System—CD40LG—systemic scleroderma	1.93e-05	0.000164	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—CD40LG—systemic scleroderma	1.93e-05	0.000164	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CSK—systemic scleroderma	1.92e-05	0.000163	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—EDN1—systemic scleroderma	1.91e-05	0.000162	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HSPG2—systemic scleroderma	1.89e-05	0.000161	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CTLA4—systemic scleroderma	1.88e-05	0.00016	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—RHOB—systemic scleroderma	1.87e-05	0.000159	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—MMP2—systemic scleroderma	1.87e-05	0.000159	CbGpPWpGaD
Sorafenib—HTR2C—GPCR ligand binding—CCL2—systemic scleroderma	1.86e-05	0.000158	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—CCL2—systemic scleroderma	1.85e-05	0.000158	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—HSPG2—systemic scleroderma	1.84e-05	0.000157	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL1A—systemic scleroderma	1.84e-05	0.000156	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL1A—systemic scleroderma	1.83e-05	0.000156	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—HSPG2—systemic scleroderma	1.83e-05	0.000155	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CD40LG—systemic scleroderma	1.83e-05	0.000155	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CSK—systemic scleroderma	1.83e-05	0.000155	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CD40LG—systemic scleroderma	1.82e-05	0.000155	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.79e-05	0.000152	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HSPG2—systemic scleroderma	1.77e-05	0.00015	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—MMP9—systemic scleroderma	1.76e-05	0.000149	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HLA-DQB1—systemic scleroderma	1.74e-05	0.000148	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.74e-05	0.000148	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—EDN1—systemic scleroderma	1.73e-05	0.000147	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—NOS3—systemic scleroderma	1.72e-05	0.000146	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CSK—systemic scleroderma	1.71e-05	0.000145	CbGpPWpGaD
Sorafenib—MAPK11—Developmental Biology—TGFB1—systemic scleroderma	1.69e-05	0.000144	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—CCL2—systemic scleroderma	1.67e-05	0.000142	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—EDN1—systemic scleroderma	1.67e-05	0.000142	CbGpPWpGaD
Sorafenib—CDK7—Disease—NOS3—systemic scleroderma	1.66e-05	0.000141	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—NOS3—systemic scleroderma	1.65e-05	0.00014	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL1A—systemic scleroderma	1.65e-05	0.00014	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—CTGF—systemic scleroderma	1.65e-05	0.00014	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—CTGF—systemic scleroderma	1.65e-05	0.00014	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CD40LG—systemic scleroderma	1.64e-05	0.00014	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—MMP9—systemic scleroderma	1.63e-05	0.000138	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—EDN1—systemic scleroderma	1.62e-05	0.000138	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—EDN1—systemic scleroderma	1.62e-05	0.000138	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—RHOB—systemic scleroderma	1.62e-05	0.000138	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—MMP9—systemic scleroderma	1.6e-05	0.000136	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.59e-05	0.000135	CbGpPWpGaD
Sorafenib—MKNK1—Disease—TGFB1—systemic scleroderma	1.56e-05	0.000133	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HLA-DQB1—systemic scleroderma	1.55e-05	0.000132	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—EDN1—systemic scleroderma	1.54e-05	0.000131	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HSPG2—systemic scleroderma	1.53e-05	0.00013	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—NOS3—systemic scleroderma	1.49e-05	0.000126	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CSK—systemic scleroderma	1.47e-05	0.000125	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL1A—systemic scleroderma	1.47e-05	0.000125	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CD40LG—systemic scleroderma	1.46e-05	0.000124	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—TGFB1—systemic scleroderma	1.45e-05	0.000123	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—MMP9—systemic scleroderma	1.41e-05	0.00012	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—EDN1—systemic scleroderma	1.4e-05	0.000119	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—CTGF—systemic scleroderma	1.4e-05	0.000119	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—EDN1—systemic scleroderma	1.4e-05	0.000119	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—CTGF—systemic scleroderma	1.39e-05	0.000118	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—EDN1—systemic scleroderma	1.38e-05	0.000118	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.35e-05	0.000115	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—TGFB1—systemic scleroderma	1.35e-05	0.000115	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—HSPG2—systemic scleroderma	1.35e-05	0.000115	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—TGFB1—systemic scleroderma	1.34e-05	0.000114	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—MMP9—systemic scleroderma	1.33e-05	0.000113	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—HSPG2—systemic scleroderma	1.32e-05	0.000112	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—TGFB1—systemic scleroderma	1.32e-05	0.000112	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—EDN1—systemic scleroderma	1.26e-05	0.000107	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—EDN1—systemic scleroderma	1.26e-05	0.000107	CbGpPWpGaD
Sorafenib—BRAF—Disease—NOS3—systemic scleroderma	1.2e-05	0.000102	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EDN1—systemic scleroderma	1.2e-05	0.000102	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—MMP9—systemic scleroderma	1.19e-05	0.000101	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EDN1—systemic scleroderma	1.19e-05	0.000101	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—CCL2—systemic scleroderma	1.19e-05	0.000101	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	1.17e-05	9.94e-05	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—TGFB1—systemic scleroderma	1.16e-05	9.86e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—HSPG2—systemic scleroderma	1.14e-05	9.73e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—CCL2—systemic scleroderma	1.14e-05	9.69e-05	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—TGFB1—systemic scleroderma	1.14e-05	9.67e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL1B—systemic scleroderma	1.12e-05	9.52e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CCL2—systemic scleroderma	1.11e-05	9.44e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—CCL2—systemic scleroderma	1.11e-05	9.42e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—TGFB1—systemic scleroderma	1.1e-05	9.34e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—NOS3—systemic scleroderma	1.1e-05	9.32e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—TGFB1—systemic scleroderma	1.09e-05	9.29e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EDN1—systemic scleroderma	1.07e-05	9.13e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—NOS3—systemic scleroderma	1.04e-05	8.84e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—NOS3—systemic scleroderma	1.04e-05	8.82e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—CTGF—systemic scleroderma	1.02e-05	8.71e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EDN1—systemic scleroderma	1.02e-05	8.71e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—HSPG2—systemic scleroderma	1.02e-05	8.69e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—NOS3—systemic scleroderma	1.02e-05	8.63e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL1B—systemic scleroderma	1.01e-05	8.59e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL1B—systemic scleroderma	1.01e-05	8.59e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—CTGF—systemic scleroderma	1e-05	8.52e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—HSPG2—systemic scleroderma	9.97e-06	8.48e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—NOS3—systemic scleroderma	9.89e-06	8.41e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—TGFB1—systemic scleroderma	9.83e-06	8.36e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL1B—systemic scleroderma	9.58e-06	8.15e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EDN1—systemic scleroderma	9.57e-06	8.14e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—CCL2—systemic scleroderma	9.56e-06	8.13e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL1B—systemic scleroderma	9.56e-06	8.13e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CCL2—systemic scleroderma	9.55e-06	8.12e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CCL2—systemic scleroderma	9.46e-06	8.04e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—HSPG2—systemic scleroderma	9.4e-06	7.99e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—NOS3—systemic scleroderma	9.34e-06	7.95e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—HSPG2—systemic scleroderma	9.31e-06	7.92e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CTGF—systemic scleroderma	8.67e-06	7.38e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL1B—systemic scleroderma	8.61e-06	7.32e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CCL2—systemic scleroderma	8.61e-06	7.32e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CCL2—systemic scleroderma	8.61e-06	7.32e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—NOS3—systemic scleroderma	8.51e-06	7.24e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—NOS3—systemic scleroderma	8.43e-06	7.17e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—NOS3—systemic scleroderma	8.33e-06	7.08e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EDN1—systemic scleroderma	8.26e-06	7.03e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CCL2—systemic scleroderma	8.17e-06	6.95e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CCL2—systemic scleroderma	8.15e-06	6.93e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—MMP9—systemic scleroderma	8.15e-06	6.93e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—TGFB1—systemic scleroderma	7.96e-06	6.77e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—HSPG2—systemic scleroderma	7.96e-06	6.77e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—MMP9—systemic scleroderma	7.94e-06	6.75e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CTGF—systemic scleroderma	7.74e-06	6.58e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL1B—systemic scleroderma	7.68e-06	6.53e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—NOS3—systemic scleroderma	7.67e-06	6.52e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—NOS3—systemic scleroderma	7.67e-06	6.52e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CTGF—systemic scleroderma	7.56e-06	6.43e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CCL2—systemic scleroderma	7.34e-06	6.24e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NOS3—systemic scleroderma	7.28e-06	6.19e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NOS3—systemic scleroderma	7.26e-06	6.18e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—TGFB1—systemic scleroderma	7.24e-06	6.16e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—NOS3—systemic scleroderma	7.17e-06	6.1e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—NOS3—systemic scleroderma	7.17e-06	6.1e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CTGF—systemic scleroderma	7.12e-06	6.06e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CTGF—systemic scleroderma	7.06e-06	6e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCL2—systemic scleroderma	7e-06	5.95e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—TGFB1—systemic scleroderma	6.88e-06	5.85e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—TGFB1—systemic scleroderma	6.86e-06	5.83e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MMP9—systemic scleroderma	6.83e-06	5.81e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MMP9—systemic scleroderma	6.76e-06	5.75e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TGFB1—systemic scleroderma	6.71e-06	5.71e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NOS3—systemic scleroderma	6.54e-06	5.56e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCL2—systemic scleroderma	6.54e-06	5.56e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TGFB1—systemic scleroderma	6.54e-06	5.56e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NOS3—systemic scleroderma	6.24e-06	5.31e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—TGFB1—systemic scleroderma	6.18e-06	5.25e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MMP9—systemic scleroderma	6.16e-06	5.23e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MMP9—systemic scleroderma	6.16e-06	5.23e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—HSPG2—systemic scleroderma	6.14e-06	5.22e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—NOS3—systemic scleroderma	6.08e-06	5.17e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CTGF—systemic scleroderma	6.03e-06	5.13e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—NOS3—systemic scleroderma	6.03e-06	5.13e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MMP9—systemic scleroderma	5.84e-06	4.97e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NOS3—systemic scleroderma	5.83e-06	4.96e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MMP9—systemic scleroderma	5.83e-06	4.96e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCL2—systemic scleroderma	5.65e-06	4.8e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TGFB1—systemic scleroderma	5.63e-06	4.78e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TGFB1—systemic scleroderma	5.57e-06	4.74e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—TGFB1—systemic scleroderma	5.51e-06	4.68e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MMP9—systemic scleroderma	5.25e-06	4.46e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TGFB1—systemic scleroderma	5.07e-06	4.31e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TGFB1—systemic scleroderma	5.07e-06	4.31e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NOS3—systemic scleroderma	5.03e-06	4.28e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MMP9—systemic scleroderma	5.01e-06	4.26e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TGFB1—systemic scleroderma	4.81e-06	4.09e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TGFB1—systemic scleroderma	4.8e-06	4.08e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP9—systemic scleroderma	4.68e-06	3.98e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CTGF—systemic scleroderma	4.66e-06	3.96e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—NOS3—systemic scleroderma	4.46e-06	3.79e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—NOS3—systemic scleroderma	4.36e-06	3.71e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TGFB1—systemic scleroderma	4.33e-06	3.68e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TGFB1—systemic scleroderma	4.13e-06	3.51e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP9—systemic scleroderma	4.04e-06	3.43e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TGFB1—systemic scleroderma	3.86e-06	3.28e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—NOS3—systemic scleroderma	3.78e-06	3.21e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—NOS3—systemic scleroderma	3.37e-06	2.87e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TGFB1—systemic scleroderma	3.33e-06	2.83e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—NOS3—systemic scleroderma	3.29e-06	2.8e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—NOS3—systemic scleroderma	3.1e-06	2.64e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—NOS3—systemic scleroderma	3.07e-06	2.61e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—NOS3—systemic scleroderma	2.63e-06	2.23e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NOS3—systemic scleroderma	2.03e-06	1.72e-05	CbGpPWpGaD
